FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2268333005> ?p ?o ?g. }

• W2268333005 endingPage "8519" @default.
• W2268333005 startingPage "8519" @default.
• W2268333005 abstract "8519^ Background: Vascular endothelial growth factor (VEGF)-mediated angiogenesis contributes to MM pathogenesis. Ramucirumab is a recombinant human monoclonal antibody (MAb) that inhibits VEGF receptor-2 (VEGFR-2) binding and signaling. This study in chemotherapy- naïve pts investigates ramucirumab in combination with DTIC and as monotherapy. Methods: Eligible pts had stage IV disease of cutaneous origin, ECOG PS 0-1, and adequate hematologic, hepatic and renal function. Therapy (Rx) in Arm A was ramucirumab (10 mg/kg) + DTIC (1,000 mg/m2) and in Arm B was ramucirumab (10 mg/kg) every (q) 3 weeks (wk); tumor assessments were q6 wk. The primary endpoint is progression-free survival (PFS); other endpoints are safety, response, and pharmacokinetic (PK)/pharmacodynamic (PD) profiles. Results: 105 pts were randomized; 102 received study Rx. On Arm A (n = 52) median age was 63, 71% were male, ≥ 27% had elevated LDH. On Arm B (n = 50) median age was 62, 72% were male, ≥ 36% had elevated LDH. Preliminary median PFS was 2.5 months (m) on Arm A and 1.6 m on Arm B; 6 m PFS rates were 31% and 15%, and 12 m PFS rates were 23% and 15% on Arms A and B, respectively. There were 2 (4%) PR and 25 (48%) SD, and 2 (4%) PR and 19 (38%) SD on Arms A and B, respectively. Nonhematologic adverse events (AEs) considered at least possibly related to ramucirumab included fatigue (29%; 2% grade [G] ≥ 3), hypertension (HTN; 19%; 12% G ≥ 3), infusion related reactions (IRR; 8%; 0 G ≥ 3), proteinuria (PU; 8%; 4% G ≥ 3), headache (HA; 8%; 2% G ≥ 3) on Arm A; and fatigue (24%; 2% G ≥ 3), HTN (20%; 10% G ≥ 3), IRR (14%; 6% G ≥ 3), PU (8%; 2% G ≥ 3), HA (20%; 0 G ≥ 3) on Arm B. IRR incidence on both arms was reduced following a recommendation for premedication after 37 pts began Rx. Hematologic AEs were neutropenia (NP; 29%; 25% G ≥ 3), thrombocytopenia (TP; 31; 12% G ≥ 3), and anemia (A;12%; 4% G ≥ 3) on Arm A; and NP (0%), TP (8%; 2% G ≥ 3) and A (2%; 0 G ≥ 3) on Arm B. Cmin concentrations beyond Cycle 1 exceeded the target trough concentration associated with preclinical efficacy (20 mg/mL). Conclusions: Ramucirumab is well tolerated in MM. Ramucirumab/DTIC may be associated with improved 6m PFS relative to monoRx; long-term disease control was noted in each study arm. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen, Genomic Health, sanofi-aventis Amgen, Genomic Health, sanofi-aventis In compliance with the guidelines established by the ASCO Conflict of Interest Policy (J Clin Oncol. 2006 Jan 20;24[3]:519-521) and the Accreditation Council for Continuing Medical Education (ACCME), ASCO strives to promote balance, independence, objectivity, and scientific rigor through disclosure of financial and other interests, and identification and management of potential conflicts. According to the ASCO Conflict of Interest Policy, the following financial and other relationships must be disclosed: employment or leadership position, consultant or advisory role, stock ownership, honoraria, research funding, expert testimony, and other remuneration (J Clin Oncol. 2006 Jan 20;24[3]:520). The ASCO Conflict of Interest Policy disclosure requirements apply to all authors who submit abstracts to the Annual Meeting. For clinical trials that began accrual on or after April 29, 2004, ASCO's Policy places some restrictions on the financial relationships of principal investigators (J Clin Oncol. 2006 Jan 20;24[3]:521). If a principal investigator holds any restricted relationships, his or her abstract will be ineligible for placement in the 2010 Annual Meeting unless the ASCO Ethics Committee grants an exception. Among the circumstances that might justify an exception are that the principal investigator (1) is a widely acknowledged expert in a particular therapeutic area; (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research. NIH-sponsored trials are exempt from the Policy restrictions. Abstracts for which authors requested and have been granted an exception in accordance with ASCO's Policy are designated with a caret symbol (^) in the Annual Meeting Proceedings. For more information about the ASCO Conflict of Interest Policy and the exceptions process, please visit www.asco.org/conflictofinterest." @default.
• W2268333005 created "2016-06-24" @default.
• W2268333005 creator A5008391854 @default.
• W2268333005 creator A5010628808 @default.
• W2268333005 creator A5017563014 @default.
• W2268333005 creator A5018099630 @default.
• W2268333005 creator A5034331469 @default.
• W2268333005 creator A5041743427 @default.
• W2268333005 creator A5067238310 @default.
• W2268333005 creator A5082726917 @default.
• W2268333005 creator A5086473468 @default.
• W2268333005 creator A5089379108 @default.
• W2268333005 date "2010-05-20" @default.
• W2268333005 modified "2023-09-27" @default.
• W2268333005 title "A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM)." @default.
• W2268333005 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.8519" @default.
• W2268333005 hasPublicationYear "2010" @default.
• W2268333005 type Work @default.
• W2268333005 sameAs 2268333005 @default.
• W2268333005 citedByCount "6" @default.
• W2268333005 countsByYear W22683330052013 @default.
• W2268333005 crossrefType "journal-article" @default.
• W2268333005 hasAuthorship W2268333005A5008391854 @default.
• W2268333005 hasAuthorship W2268333005A5010628808 @default.
• W2268333005 hasAuthorship W2268333005A5017563014 @default.
• W2268333005 hasAuthorship W2268333005A5018099630 @default.
• W2268333005 hasAuthorship W2268333005A5034331469 @default.
• W2268333005 hasAuthorship W2268333005A5041743427 @default.
• W2268333005 hasAuthorship W2268333005A5067238310 @default.
• W2268333005 hasAuthorship W2268333005A5082726917 @default.
• W2268333005 hasAuthorship W2268333005A5086473468 @default.
• W2268333005 hasAuthorship W2268333005A5089379108 @default.
• W2268333005 hasConcept C126322002 @default.
• W2268333005 hasConcept C141071460 @default.
• W2268333005 hasConcept C143998085 @default.
• W2268333005 hasConcept C168563851 @default.
• W2268333005 hasConcept C197934379 @default.
• W2268333005 hasConcept C203092338 @default.
• W2268333005 hasConcept C2776694085 @default.
• W2268333005 hasConcept C2779551604 @default.
• W2268333005 hasConcept C2780964509 @default.
• W2268333005 hasConcept C31760486 @default.
• W2268333005 hasConcept C71924100 @default.
• W2268333005 hasConcept C90924648 @default.
• W2268333005 hasConceptScore W2268333005C126322002 @default.
• W2268333005 hasConceptScore W2268333005C141071460 @default.
• W2268333005 hasConceptScore W2268333005C143998085 @default.
• W2268333005 hasConceptScore W2268333005C168563851 @default.
• W2268333005 hasConceptScore W2268333005C197934379 @default.
• W2268333005 hasConceptScore W2268333005C203092338 @default.
• W2268333005 hasConceptScore W2268333005C2776694085 @default.
• W2268333005 hasConceptScore W2268333005C2779551604 @default.
• W2268333005 hasConceptScore W2268333005C2780964509 @default.
• W2268333005 hasConceptScore W2268333005C31760486 @default.
• W2268333005 hasConceptScore W2268333005C71924100 @default.
• W2268333005 hasConceptScore W2268333005C90924648 @default.
• W2268333005 hasIssue "15_suppl" @default.
• W2268333005 hasLocation W22683330051 @default.
• W2268333005 hasOpenAccess W2268333005 @default.
• W2268333005 hasPrimaryLocation W22683330051 @default.
• W2268333005 hasRelatedWork W2024575798 @default.
• W2268333005 hasRelatedWork W2084815211 @default.
• W2268333005 hasRelatedWork W2268296423 @default.
• W2268333005 hasRelatedWork W2268333005 @default.
• W2268333005 hasRelatedWork W2799607207 @default.
• W2268333005 hasRelatedWork W2912403850 @default.
• W2268333005 hasRelatedWork W2942064441 @default.
• W2268333005 hasRelatedWork W2949761024 @default.
• W2268333005 hasRelatedWork W3041235120 @default.
• W2268333005 hasRelatedWork W4226504180 @default.
• W2268333005 hasVolume "28" @default.
• W2268333005 isParatext "false" @default.
• W2268333005 isRetracted "false" @default.
• W2268333005 magId "2268333005" @default.
• W2268333005 workType "article" @default.